We describe a 6-year-old boy with histologically con®rmed pancreatoblastoma and a markedly elevated serum a-fetoprotein (AFP) concentration. Due to local tumour invasion, cytotoxic chemotherapy was given to debulk the tumour before attempting surgical resection. Serial serum AFP concentrations were measured on this patient. During chemotherapy there was a 495% fall in total AFP. Tumour-speci®c variants of AFP, detected by isoelectric focusing, also disappeared during chemotherapy but recurred when chemotherapy was withdrawn. It is suggested that although there was no change in overall size of the tumour, as assessed by various imaging techniques, the changes in serological markers may indicate that the treatment did in fact cause considerable tumour necrosis. AFP and its variants may be useful markers of tumour response in patients with pancreatoblastoma. The expression of AFP and its variants in pancreatoblastoma may be related to the embryonic origin of the pancreas.
Pancreatoblastoma is a rare childhood malignancy, with only 55 cases reported according to a 1995 review. 1 Subsequently, there have been seven further cases published, making the total number of cases 62. 2, 3 The combination of an abdominal mass and obstructive jaundice associated with an elevated serum a-fetoprotein (AFP) concentration is the usual presentation. 1 a-fetoprotein is a heterogenous oncofoetal glycoprotein with an approximate molecular weight of 70 kDa. It has been used widely as a serological marker for the diagnosis and monitoring of hepatocellular carcinoma, non-seminomatous germ cell tumours and various other gastrointestinal malignancies. 4±7 To increase the speci®city of this tumour marker, attempts have been made to exploit tumour-speci®c differences in the carbohydrate structure of AFP using isoelectric focusing (IEF) at pH 4´5 to 5´4. 8, 9 Three major variants (known as bands +I, +II and +III) can be identi®ed by IEF in hepatocellular carcinoma (bands +I and +II) 10 and germ cell tumours (bands +II and +III). 9 AFP is also a tumour marker for pancreatoblastoma, 11, 12 but to date there has been no report on any associated AFP variants.
We report here a case of pancreatoblastoma and the changes of AFP variants at different stages of treatment.
CASE REPORT
SW, second child of the family, was a 6-year-old boy born at full term by Caesarean section from non-consanguineous parents. Signi®cant past medical history included ventricular septal defect and patent ductus arteriosus repaired by open heart surgery, bilateral undescended testes with orchidopexy performed, left herniotomy with gut resection for incarcerated hernia, and glucose-6-phosphate dehydrogenase de®ciency diagnosed at birth. He presented at 5 years of age with marked weight loss, abdominal distension, pale stools and fatty diarrhoea which had developed over a 2-month period.
Computerized tomography of the thorax and abdomen showed a huge enhancing mass with irregular outline in the retroperitoneum, but no de®nite para-aortic nodules could be demonstrated. Laparotomy was performed and a vascular tumour was found in the lesser sac, which was not resectable because of ®xation to underlying tissues. Histological examination of tissue taken from the tumour was consistent with a diagnosis of pancreatoblastoma. Bone scan revealed no evidence of bony metastasis.
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Ultrasound of the abdomen revealed massive hepatosplenomegaly. Laboratory investigations showed markedly elevated serum AFP concentration (3130 mg/L), together with deranged liver function tests suggestive of obstructive jaundice (see Table 1 ). Chemotherapy, according to the protocol of Inomata et al., 13 was initiated for debulking the tumour before a further attempt at surgical resection. 14 Two cycles of adriamycin and cisplatin (chemotherapy I) were given. This was later changed to actinomycin D and cyclophosphamide (chemotherapy II) because of persistently deranged liver function. However, the tumour size remained static, encasing the base of the small bowel mesentery. Liver metastases were also present. The patient progressively deteriorated and eventually died of renal failure 7 months after diagnosis.
MATERIALS AND METHODS

Patient and control serum samples
Serial clotted blood samples were collected throughout the course of chemotherapy for serum AFP assay. Five of these samples were used to study the glycosylation variants at different stages of treatment: at presentation (A), during chemotherapy I (B), during chemotherapy II (C), just after withdrawal of chemotherapy (D), and just prior to the death of the patient (E). Two serum samples from patients with hepatocellular carcinoma were used as controls for identi®cation of the AFP variants. One of them contained mainly bands +I and +II (H2), and the other bands +II and +III (H1). . The focused proteins were then transferred onto a nitrocellulose membrane and reacted successively with polyclonal rabbit anti-human AFP immunoglobulin (DAKO, Glostrup, Denmark), and horseradish peroxidase-conjugated polyclonal swine anti-rabbit immunoglobulin (DAKO). After peroxidase reaction with luminol, AFP variants were visualized using the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech). The image of each band was scanned with a GS-700 densitometer (Bio-Rad Laboratories Inc, Hercules CA, USA) and its intensity expressed as a percentage of total intensity of all AFP variants. 
RESULTS
As shown in Fig. 1 , serum AFP concentration decreased markedly throughout the course of chemotherapy (3130 to 153 mg/L, 495% decrease) before gradually increasing after the withdrawal of chemotherapy until the death of the patient. Figure 2 shows the pattern of AFP variants and Fig. 3 
FIGURE 2. Study of a-fetoprotein (AFP) variants by isoelectric focusing. Controls: H1, serum from patient with hepatocellular carcinoma having AFP variant bands +II and +III; H2, serum from patient with hepatocellular carcinoma having AFP variant bands +I and +II. Patient serum: lane A, AFP variants at presentation; lane B, AFP variants during chemotherapy I; lane C, AFP variants during chemotherapy II, lane D, AFP variants after withdrawal of chemotherapy; lane E, AFP variants prior to the death of the patient.
predominant variants were band +II (40´9%) followed by band +III (39´2%), with limited bands +I (16´1%) and 7I (3´8%). There was a marked reduction in the proportion of these variants during chemotherapy (lanes B and C) at which time the predominant variants were band +I (57´2 and 63´7%) followed by band 7I (18´9 and 21´3%). Bands +II (22´2%) and +III (18´6%) quickly re-appeared after the withdrawal of chemotherapy (lane D) and further increased (25´1 and 20´7%, respectively) prior to the death of the patient (lane E).
DISCUSSION
Serum AFP concentration has been reported to be elevated in pancreatoblastoma. It can be used for diagnosis and monitoring treatment. However, routine investigation of AFP variants is not recommended because of the tedious work involved and should only be considered on a case-by-case basis. 4 In the present case, the elevated AFP concentration fell rapidly during chemotherapy and started to rise again once chemotherapy was withdrawn. Although the decline was not associated with any obvious change in tumour size it is now well recognized that, particularly in the case of liver tumours, there may be extensive necrosis and even complete pathological remission without major changes in the overall size of the tumour. 5, 15 Such responses are usually faithfully re¯ected by changes in the serum AFP concentration. The residual`tumour', identi®ed by imaging procedures, is necrotic or ®brotic tissue devoid of viable malignant cells. As the AFP concentration fell by more than 95%, this may have been so in the present case.
The associated AFP variants have not previously been investigated in pancreatoblastoma. In other more common tumours that secrete AFP, three characteristic bands, known as +I, +II and +III, represent the principal variants of AFP. The biochemical basis of these variants is related to the degree of glycosylation. There have been reports of enhanced expression of glycosyltransferase genes after oncogenic transformation. 16±18 The increased activities of glycosyltransferases may result in tumourassociated variants of the original glycoproteins. 19 In the case of AFP, the band +I variant contains two molecules of sialic acid on the carbohydrate side-chain, band +II one sialic acid and band +III no sialic acid molecule. 20 For this reason, band +III is the most basic variant (focused at pH 4´90), band +II is more 
From presentation (lane A), bands +II and +III decreased in percentage intensity during chemotherapy I (lane B) and during chemotherapy II (lane C). They started to increase again after withdrawal of chemotherapy (lane D) until prior to the death of the patient (lane E).
As expected, band +I had a reciprocal relationship with bands +II and +III. Band 7I increased and followed the trend of Band +I.
acidic (focused at pH 4´83), and band +I is yet more acidic (focused at pH 4´78). Bands +II and +III are associated with malignant disease and band +I with benign disease.
It is noteworthy that the two variants of AFP associated with malignant disease (bands +II and +III) both disappeared during treatment and recurred as chemotherapy was terminated. On the other hand, band +I (characteristically elevated in benign hepatic conditions such as cirrhosis and biliary tract obstruction) remained detectable throughout. 21, 22 These observations lend support to the contention that there is likely to have been a signi®cant histological response that was not detected by imaging techniques.
Developmentally, the pancreatic buds and the hepatic diverticulum are derived from the same endodermal lining of the foregut. 23, 24 Considering their embryonic origins, the production of AFP by tumour tissues from both liver and pancreas is perhaps not surprising. The prevalence of AFP band +III is low in hepatocellular carcinoma, 22 and more characteristic of germ cell tumours. 9 However, whether band +III is truly linked to pancreatoblastoma is dif®cult to investigate because of the rarity of this tumour.
